Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2021 Jun 1;23(Suppl 1):i18. doi: 10.1093/neuonc/noab090.072

HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA

Ilon Liu 1, Lynn Bjerke 2, Gustavo Alencastro Veiga Cruzeiro 1, Rebecca F Rogers 2, Yura Grabovska 2, Eshini Panditharatna 1, Alan Mackay 2, Tara Barron 3, McKenzie Shaw 1, Samantha E Hoffman 1, Olivia A Hack 1, Michael A Quezada 3, Joshua Dempster 4, Sara Temelso 2, Bernhard Englinger 1, Valeria Molinari 2, Hafsa M Mire 1, Li Jiang 1, Sibylle Madlener 5, Lisa Mayr 5, Christian Dorfer 5, Rene Geyeregger 6, Christopher Rota 7, Gerda Ricken 5, Sanda Alexandrescu 8, Emelie Braun 9, Miri Danan-Gotthold 9, Lijuan Hu 9, Kimberly Siletti 9, Erik Sundstroem 9, Rebecca Hodge 10, Ed Lein 10, Sameer Agnihotri 11, David D Eisenstat 12, Fernando Carceller 2, Simon Stapleton 13, Cristina Bleil 14, Angela Mastronuzzi 15, Kristina A Cole 16, Angela J Waanders 17, Angel Montero Carcaboso 18, Maria Vinci 15, Darren Hargrave 19, Christine Haberler 5, Johannes Gojo 5, Irene Slavc 5, Sten Linnarsson 9, Michelle Monje 3, Chris Jones 2, Mariella G Filbin 1
PMCID: PMC8168148

Abstract

High-grade gliomas harboring H3 G34R/V mutations exclusively occur in the cerebral hemispheres of adolescents and young adults, suggesting a distinct neurodevelopmental origin. Combining multimodal bulk and single-cell genomics with unbiased genome-scale CRISPR/Cas9 approaches, we here describe a GABAergic interneuron progenitor lineage as the most likely context from which these H3 G34R/V mutations drive gliomagenesis, conferring unique and tumor-selective gene targets essential for glioma cell survival, as validated genetically and pharmacologically. Phenotypically, we demonstrate that while H3 G34R/V glioma cells harbor the neurotransmitter GABA, they are developmentally stalled, and do not induce the neuronal hyperexcitability described in other glioma subtypes. These findings offer a striking counter-example to the prevailing view of glioma origins in glial precursor cells, resulting in distinct cellular, microenvironmental, and therapeutic consequences.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES